Publications

Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, Sterle H, Flaqué MCDíaz, Magro C, Marullo R et al..  2022.  Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.. Mol Cancer Ther. 21(9):1485-1496.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al..  2017.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.

Pera B, Tang T, Marullo R, Yang S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J et al..  2016.  Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.. Clin Epigenetics. 8:79.

Ruan J, Luo M, Wang C, Fan L, Yang SNing, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L et al..  2013.  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.. Blood. 121(26):5192-202.

Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.